PF-Atlas › Клинические испытания › NCT00004533
Phase I Randomized Study of Adeno-Associated Virus-CFTR Vector in Patients With Cystic Fibrosis
Adeno-associated virus-CFTR vector · Фаза 1
ID реестра
NCT00004533
Фаза
Фаза 1
Статус
Завершено
Препарат / вмешательство
Adeno-associated virus-CFTR vector
Спонсор
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Начало
1999-08
Набор участников
19
Об исследовании
OBJECTIVES: I. Determine the maximum tolerated dose of recombinant adeno-associated virus-CFTR vector in patients with cystic fibrosis. II. Assess the safety of this gene therapy in these patients. III. Assess the in vivo gene transfer of this vector in these patients. IV. Assess the CFTR gene expression and physiologic activity following gene transfer in these patients. V. Assess the clinical impact of CFTR gene expression following gene transfer in these patients. VI. Monitor patient immune response directed against CFTR or vector components following vector administration.
Связанные материалы
Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT00004533 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.